Science ❯ Medical Research ❯ Clinical Trials

Patient Outcomes

Maturation Techniques Cancer Survival Rates Health Technology Assessment Visual Rehabilitation Stem Cell Transplant Health Innovations Behavioral Science Vision Improvement Disease Progression Geographic Atrophy Relapse Prevention Health Equity Nephrotic Syndrome Biological Mapping Survival Rates Behavioral Medicine

FDA Approves Filspari to Reduce Proteinuria in FSGS Patients Without Nephrotic Syndrome

The decision is based on a 108-week study where the drug beat irbesartan, giving a new option for a rare kidney disease.

Slow Tapering With Therapy Matches Staying on Antidepressants, Major Review Finds

AI Analyzes Full Medical Records to Personalize Anticoagulant Use in Atrial Fibrillation